Agricultural University of Athens
Η επίδραση της χρονοδιατροφής στη γλυκαιμική απόκριση και σε ανθρωπομετρικούς δείκτες
Abstract
dc:descriptionBackground: The Mediterranean Diet (MD), a dietary pattern characteristic of Mediterranean countries, has been extensively studied for its health benefits, including improving cardiometabolic profile and liver steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the most common cause of chronic liver disease worldwide. At the same time, recent years have emphasized that timing is an important factor affecting the metabolism and the metabolic functions of human tissues, such as the liver, and the hormones secreted by the endocrine glands. To date, only a few randomized controlled trials have examined the effects of time-restricted feeding (TRF), a chrononutrition strategy, on body weight, glucose metabolism, and other health parameters in patients with MASLD, and none have compared TRF to MD, which is considered the gold standard in this population. Aims: The evaluation of the effects of certain chrononutrition parameters on glycemic responses and anthropometric indices. More specifically, the primary objectives of this thesis were: 1) To investigate the effects of the various TRF protocols on body composition, glycemia, and insulin resistance, depending on body mass index (BMI) and the health status of individuals, with the ultimate aim of elucidating the research gaps around TRF and selecting the appropriate feeding and fasting window, as well as the population of the long-term clinical trial, 2) To compare the effects of TRF, within the framework of a hypocaloric MD, against the corresponding diet without any time constraints, concerning liver steatosis, glucose metabolism, and body weight (evaluation of superiority of chrononutrition), as well as other health-related parameters in individuals with MASLD and overweight/obesity, and 3) To investigate the superiority or not of restricting feeding early versus late in the day in metabolic parameters and quality of life, in this population, in the context of MD. Methods: A) The protocol for the systematic review was registered and published by PROSPERO (CRD42022321108) and was organized according to PRISMA guidelines. Two independent researchers conducted a systematic literature search for relevant studies from May 2022 to August 2022 in the PUBMED and SCOPUS databases using specific keywords. The revised Cochrane risk-of-bias tool for randomized clinical trials was utilized to assess bias. B) The 12-week, controlled trial of parallel design (NCT05866744) enrolled individuals with MASLD and overweight/obesity. They were randomized to one of the three intervention groups, all following a hypocaloric MD plan. The control group (C) had no time restriction in feeding. The early TRF (eTRF) and late TRF (lTRF) groups had a 10-hour eating window, from 08:00 to 18:00 and 12:00 to 22:00, respectively. Various health parameters were determined during the study. Compliance was tracked via food diaries, and an 8-week follow-up occurred post-intervention. Results: A) Twenty-four studies met the inclusion criteria for the systematic review. The main findings of the review were as follows: 1) TRF may result in moderate weight loss in individuals with overweight/obesity; when TRF is combined with continuous caloric restriction, weight loss exceeds 5% of the initial body weight, 2) 14 hours of fasting per day may be as effective as 16 hours in terms of weight loss, and 3) TRF may lead to improved insulin sensitivity and glycemic responses/variability throughout the day in individuals with overweight/obesity. B) Fifty-nine individuals with MASLD (27 males, 45.8%) aged 52.9±1.6 years with a BMI of 32.1±0.6 kg/m2 completed the clinical trial (C, n=19; eTRF, n=20; lTRF, n=20). At 12 weeks, compared to the baseline, significant: a) weight loss, b) reduction in body fat, c) reduction in waist circumference, d) reduction in systolic and diastolic blood pressure, and e) improvement in liver steatosis, were observed in all 3 groups, but without difference between them. In addition, the eTRF group decreased glycated hemoglobin A1c and improved insulin resistance at 12 weeks compared to the baseline. Conclusions: A) The systematic review concluded that TRF may be an effective nutritional approach for weight loss while, also, ameliorating glycemic control and insulin sensitivity in individuals with overweight/obesity. B) The clinical trial confirmed the effectiveness of MD in improving cardiometabolic risk factors such as body weight in individuals with MASLD. Notably, combining MD with eTRF enhanced glycemic control. However, late eating within the MD framework did not impair glucose metabolism or cardiometabolic profile, highlighting the importance of a balanced diet for those who eat late due to lifestyle. TRF, within the MD context, may be an acceptable alternative strategy for individuals with MASLD.
Degree
thesis:*- Grantor dc:publisher
- Agricultural University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsitsou, Sofia
- Τσίτσου, Σοφία
Subjects
dc:subject × 18- Ανθρωπομετρία
- Μεσογειακή διατροφή
- Μεταβολικά-σχετιζόμενη στεατωτική νόσος ήπατος
- Μεταβολισμός γλυκόζης
- Χρονικά περιορισμένη λήψη τροφής
- Χρονοδιατροφή
- Anthropometry
- Chrononutrition
- Glucose metabolism
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Mediterranean diet
- Time-restricted feeding
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Διατροφή και Διαιτολογία
- Health Sciences
- Medical and Health Sciences
- Nutrition and Dietetics
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59529